Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242015233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mohd Nazzary Mamat Yusof und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gynaecologic-Oncology Unit, Department of Obstetrics and Gynaecology, Hospital Canselor Tuanku Muhriz, Faculty of Medicine, Universiti Kebangsaan Mal…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Endometrial Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Grant Scheme by the Ministry of Higher Education Malaysia.
Abstract (Originalsprache)
The landscape of diagnosing and treating endometrial cancer is undergoing a profound transformation due to the integration of molecular analysis and innovative therapeutic approaches. For several decades, the cornerstone treatments for endometrial cancer have included surgical resection, cytotoxic chemotherapy, hormonal therapy, and radiation therapy. However, in recent years, the concept of personalised medicine has gained momentum, reshaping the way clinicians approach cancer treatment. Tailoring treatments based on specific biomarkers has evolved into a standard practice in both initial and recurrent therapy protocols. This review aims to provide an in-depth exploration of the current state of molecular analysis and treatment strategies in the context of endometrial cancer, focusing on the immunological aspect of the PD-1/PD-L1 axis. Furthermore, it seeks to shed light on emerging and innovative approaches that hold promise for the future modulation of endometrial cancer treatments. In essence, as researchers delve into the complex molecular landscape of endometrial cancer and harness the understanding of the PD-1/PD-L1 axis, we are paving the way for more targeted, effective, and personalised therapies that have the potential to significantly improve the outcomes and quality of life for patients with this challenging disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynaecologic-Oncology Unit, Department of Obstetrics and Gynaecology, Hospital Canselor Tuanku Muhriz, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.
ORCID-Profile: Mohd Nazzary Mamat Yusof, Kah Teik Chew, Nirmala Chandralega Kampan
Förderung
- Fundamental Research Grant Scheme by the Ministry of Higher Education Malaysia
Zitieren
APA
Mamat Yusof, M. N., Chew, K. T., Kampan, N. C., & Shafiee, M. N. (2023). Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242015233
Vancouver
Mamat Yusof MN, Chew KT, Kampan NC, Shafiee MN. Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242015233
BibTeX
@article{MamatYusof2023,
author = {Mamat Yusof, Mohd Nazzary and Chew, Kah Teik and Kampan, Nirmala Chandralega and Shafiee, Mohamad Nasir},
title = {Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242015233}
}
EUVIMED